Claims
- 1. A method of improving DNA repair in the skin or mucosa of a mammal comprising administering to said mammal at least one deoxyribonucleoside, deoxyribonucleotide, or oligodeoxyribonucleotide.
- 2. A method as in claim 1 wherein said at least one deoxyribonucleoside is administered topically.
- 3. A method as in claim 1 wherein said at least one deoxyribonucleoside is selected from the group consisting of deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 4. A method as in claim 3 wherein said at least one deoxyribonucleoside is deoxycytidine.
- 5. A method as in claim 3 wherein said at least one deoxyribonucleoside is deoxyadenosine.
- 6. A method as in claim 3 wherein said at least one deoxyribonucleoside is deoxyguanosine.
- 7. A method as in claim 3 wherein said at least one deoxyribonucleoside is thymidine.
- 8. A method as in claim 3 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 9. A method as in claim 3 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 1.0 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 10. A method as in claim 3 wherein said at least one deoxyribonucleoside is a mixture of deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 11. A method as in claim 10 wherein said deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 12. A method as in claim 10 wherein said deoxyribonucleoside is administered in a vehicle containing from 1 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 13. A method for reducing mutation frequency in skin of a mammal exposed to a mutagen comprising administering to said skin a source of at least one deoxyribonucleoside.
- 14. A method as in claim 13 wherein said mutagen is selected from the group consisting of ultraviolet or solar radiation, a chemical mutagen, a free radical, or ionizing radiation.
- 15. A method as in claim 13 wherein said source is selected from the group consisting of at least one free or acyl deoxyribonucleoside.
- 16. A method as in claim 13 wherein said source is selected from the group consisting of a deoxyribonucleotide, an oligodeoxyribonucleotide, and a polydeoxyribonucleotide.
- 17. A method as in claim 13 wherein said source of at least one deoxyribonucleoside is administered in a vehicle at a concentration of from 1.0 to 20 milligrams per milliliter.
- 18. A method as in claim 15 wherein said at least one deoxyribonucleoside is free or acyl deoxycytidine.
- 19. A method as in claim 15 wherein said at least one deoxyribonucleoside is free or acyl deoxyadenosine.
- 20. A method as in claim 15 wherein said at least one deoxyribonucleoside is free or acyl deoxyguanosine.
- 21. A method as in claim 15 wherein said at least one deoxyribonucleoside is free or acyl thymidine.
- 22. A method as in claim 15 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 23. A method as in claim 15 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 1.0 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 24. A method as in claim 15 wherein said at least one deoxyribonucleoside is a mixture of free or acyl deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 25. A method as in claim 24 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 26. A method as in claim 24 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 1 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 27. A method for reducing the chance of developing skin cancer in a mammal due to exposure to a mutagen comprising administering to the skin of said mammal a source of at least one deoxyribonucleoside wherein said source is administered such that said at least one deoxyribonucleoside is present on skin of said mammal during or after exposure to said mutagen in an amount sufficient to reduce the deleterious consequences of said exposure.
- 28. A method as in claim 27 wherein said source is administered within 3 days after exposure to a mutagen.
- 29. A method as in claim 28 wherein said mutagen is selected from the group consisting of solar, ultraviolet, or ionizing radiation.
- 30. A method as in claim 27 wherein said source is selected from the group consisting of at least one free or acyl deoxyribonucleoside.
- 31. A method as in claim 27 wherein said source is selected from the group consisting of a deoxyribonucleotide, an oligodeoxyribonucleotide, and a polydeoxyribonucleotide.
- 32. A method as in claim 27 wherein said source of at least one deoxyribonucleoside is administered in a vehicle at a concentration of from 1.0 to 20 milligrams per milliliter.
- 33. A method as in claim 30 wherein said at least one deoxyribonucleoside is free or acyl deoxycytidine.
- 34. A method as in claim 30 wherein said at least one deoxyribonucleoside is free or acyl deoxyadenosine.
- 35. A method as in claim 30 wherein said at least one deoxyribonucleoside is free or acyl deoxyguanosine.
- 36. A method as in claim 30 wherein said at least one deoxyribonucleoside is free or acyl thymidine.
- 37. A method as in claim 30 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 38. A method as in claim 30 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 1.0 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 39. A method as in claim 30 wherein said at least one deoxyribonucleoside is a mixture of free or acyl deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 40. A method as in claim 39 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 41. A method as in claim 39 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 1 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 42. A method as in claim 27 wherein said skin cancer is selected from the group comprising basal cell carcinoma, melanoma, and squamous cell carcinoma.
- 43. A method for reducing the rate of skin photoaging in a mammal comprising administering to the skin of said mammal at least one deoxyribonucleoside.
- 44. A method as in claim 43 wherein said at least one deoxyribonucleoside is deoxycytidine.
- 45. A method as in claim 43 wherein said at least one deoxyribonucleoside is deoxyadenosine.
- 46. A method as in claim 43 wherein said at least one deoxyribonucleoside is deoxyguanosine.
- 47. A method as in claim 43 wherein said at least one deoxyribonucleoside is thymidine.
- 48. A method as in claim 43 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 49. A method as in claim 43 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 1.0 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 50. A method as in claim 43 wherein said at least one deoxyribonucleoside is a mixture of deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 51. A method as in claim 50 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 52. A method as in claim 50 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 1 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 53. A method for reducing the chance of developing actinic keratoses in a mammal comprising administering to the skin of said mammal a source of at least one deoxyribonucleoside.
- 54. A method as in claim 53 wherein said source is selected from the group consisting of a deoxyribonucleoside, a deoxyribonucleotide, an oligodeoxyribonucleotide, and an acyl derivatives of deoxyribonucleoside.
- 55. A method of reducing the deleterious consequences of photosensitization or photodynamic sensitization on the skin of a mammal caused by an endogenous or exogenous photochemically active chromophore comprising administering to said skin an energy scavenging agent with a lowest triplet state energy less than or equal to that of nucleobases in DNA.
- 56. A method as in claim 55 wherein said exogenous chromophore is a sunscreen agent.
- 57. A method as in claim 56 wherein said sunscreen agent is selected from the group consisting of avobenzone (t-butyl dimethoxydibenzoylmethane), oxybenzone (benzophenone-3), dioxybenzone (benzophenone-8), sulisobenzone (benzophenone-4; 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid), octocrylene (2-ethylhexyl-2-cyano-3,3-diphenylacrylate), octyl methoxycinnamate (2-ethylhexyl p-methoxycinnamate), octyl salicylate (2-ethylhexylsalicylate), homosalate (homomenthyl salicylate), trolamine salicylate (triethanolamine salicylate), phenylbenzimidazole sulfonic acid, PABA (para-aminobenzoic acid), roxadimate (ethyl 4-bis hydroxypropyl aminobenzoate), lisadimate (glyceryl PABA), Padimate O (octyldimethyl PABA), menthyl anthranilate, or Parsol 1789 (butyl methoxydibenzoylmethane)
- 58. A method as in claim 55 wherein said energy scavenging agent is selected from the group consisting of DNA, an oligodeoxyribonucleotide, a ribonucleoside, a deoxyribonucleoside, a ribonucleotide, a deoxyribonucleotide, an acyl deoxyribonucleoside, and an acyl ribonucleoside.
- 59. A method as in claim 58 wherein said energy scavenging agent is administered in a vehicle containing 0.1 to 20 mg/ml.
- 60. A method as in claim 58 wherein said energy scavenging agent is a mixture comprising free or acylated deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 61. A method as in claim 60 wherein said mixture is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 62. A method for reducing the deleterious consequences of exposure of a mutagen to the skin of a mammal comprising administering to said mammal at least one deoxyribonucleoside, deoxyribonucleotide, or oligodeoxyribonucleotide.
- 63. A method as in claim 62 wherein said mutagen is solar or ultraviolet radiation.
- 64. A method as in claim 62 wherein said mutagen is ionizing radiation.
- 65. A method as in claim 62 wherein said mutagen is a free radical.
- 66. A method as in claim 62 wherein said at least one deoxyribonucleoside is administered topically.
- 67. A method as in claim 62 wherein said at least one deoxyribonucleoside is selected from the group consisting of deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 68. A method as in claim 67 wherein said at least one deoxyribonucleoside is deoxycytidine.
- 69. A method as in claim 67 wherein said at least one deoxyribonucleoside is deoxyadenosine.
- 70. A method as in claim 67 wherein said at least one deoxyribonucleoside is deoxyguanosine.
- 71. A method as in claim 67 wherein said at least one deoxyribonucleoside is thymidine.
- 72. A method as in claim 67 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 73. A method as in claim 67 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 1.0 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 74. A method as in claim 67 wherein said at least one deoxyribonucleoside is a mixture of deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 75. A method as in claim 74 wherein said deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 76. A method as in claim 74 wherein said deoxyribonucleoside is administered in a vehicle containing from 1 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 77. A method of reducing the deleterious consequences of exposure of skin to endogenously produced nitric oxide comprising administering to said skin a source of at least one deoxyribonucleoside.
- 78. A method as in claim 77 wherein said source of at least one deoxyribonucleoside is selected from the group consisting of a deoxyribonucleoside, a deoxyribonucleotide, an oligodeoxyribonucleotide, or an acyl deoxyribonucleoside.
- 79. A method as in claim 77 wherein said source of at least one deoxyribonucleoside is administered in a vehicle at a concentration of from 1.0 to 20 milligrams per milliliter.
- 80. A method as in claim 78 wherein said at least one deoxyribonucleoside is free or acyl deoxycytidine.
- 81. A method as in claim 78 wherein said at least one deoxyribonucleoside is free or acyl deoxyadenosine.
- 82. A method as in claim 78 wherein said at least one deoxyribonucleoside is free or acyl deoxyguanosine.
- 83. A method as in claim 78 wherein said at least one deoxyribonucleoside is free or acyl thymidine.
- 84. A method as in claim 78 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 85. A method as in claim 78 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 1.0 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 86. A method as in claim 78 wherein said at least one deoxyribonucleoside is a mixture of free or acyl deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 87. A method as in claim 86 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 88. A method as in claim 86 wherein said at least one deoxyribonucleoside is administered in a vehicle containing from 1 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 89. A method of treating skin inflammation in a mammal comprising administering to inflamed skin a source of at least one deoxyribonucleoside or ribonucleoside.
- 90. A method as in claim 89 wherein said skin inflammation is selected from the group consisting of dermatitis, psoriasis, eczema, and acne.
- 91. A method as in claim 89 wherein said skin inflammation is due to exposure to solar or ultraviolet radiation.
- 92. A method as in claim 89 wherein said source of at least one deoxyribonucleoside or ribonucleoside is selected from the group consisting of DNA, an oligodeoxyribonucleotide, a ribonucleoside, a deoxyribonucleoside, a ribonucleotide, a deoxyribonucleotide, an acyl deoxyribonucleoside, and an acyl ribonucleoside.
- 93. A method as in claim 92 wherein said source of at least one deoxyribonucleoside or ribonucleoside is administered in a vehicle containing from 0.1 to 20 mg/ml.
- 94. A method as in claim 92 wherein said source of at least one deoxyribonucleoside is a mixture comprising free or acylated deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 95. A method as in claim 89 wherein said source of at least one deoxyribonucleoside is deoxycytidine.
- 96. A method as in claim 89 wherein said source of at least one ribonucleoside is adenosine.
- 97. A method as in claim 89 wherein said adenosine is administered in a vehicle containing from 0.1 to 10 mg/ml.
- 98. A method of treating mucosal inflammation in a mammal comprising administering to said mucosal inflammation a source of at least one deoxyribonucleoside or ribonucleoside.
- 99. A method as in claim 98 wherein said mucosal skin inflammation is selected from the group consisting of inflammatory bowel disease, ulcerative colitis, Crohn's disease, stomatitis or mucositis.
- 100. A method as in claim 98 wherein said source of at least one deoxyribonucleoside or ribonucleoside is selected from the group consisting of DNA, an oligodeoxyribonucleotides, a ribonucleoside, a deoxyribonucleoside, a ribonucleotide, a deoxyribonucleotide, an acyl deoxyribonucleoside, and an acyl ribonucleoside.
- 101. A method as in claim 100 wherein said source of at least one deoxyribonucleoside is administered in a vehicle containing from 0.1 to 20 mg/ml.
- 102. A method as in claim 100 wherein said source of at least one deoxyribonucleoside is a mixture comprising free or acylated deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 103. A method as in claim 98 wherein said source of at least one deoxyribonucleoside is deoxycytidine.
- 104. A method of reducing the chance of developing skin cancer in a mammal due to exposure to solar or ultraviolet radiation comprising topically administering a composition comprising a sunscreen agent and an energy scavenging agent.
- 105. A method as in claim 104 wherein said sunscreen agent is selected from the group consisting of avobenzone (t-butyl dimethoxydibenzoylmethane), oxybenzone (benzophenone-3), dioxybenzone (benzophenone-8), sulisobenzone (benzophenone4; 2-hydroxy4-methoxybenzophenone-5-sulfonic acid), octocrylene (2-ethylhexyl-2-cyano-3,3-diphenylacrylate), octyl methoxycinnamate (2-ethylhexyl p-methoxycinnamate), octyl salicylate (2-ethylhexylsalicylate), homosalate (homomenthyl salicylate), trolamine salicylate (triethanolamine salicylate), phenylbenzimidazole sulfonic acid, PABA (para-aminobenzoic acid), roxadimate (ethyl 4-bis hydroxypropyl aminobenzoate), lisadimate (glyceryl PABA), Padimate O (octyldimethyl PABA), menthyl anthranilate, or Parsol 1789 (butyl methoxydibenzoylmethane)
- 106. A method as in claim 104 wherein said energy scavenging agent is selected from the group consisting of DNA, an oligodeoxyribonucleotide, a ribonucleoside, a deoxyribonucleoside, a ribonucleotide, a deoxyribonucleotide, an acyl deoxyribonucleoside, and an acyl ribonucleoside.
- 107. A method as in claim 106 wherein said energy scavenging agent is administered in a vehicle containing from 0.1 to 20 mg/ml.
- 108. A method as in claim 106 wherein said energy scavenging agent is a mixture comprising free or acylated deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 109. A composition comprising
a) at least one deoxyribonucleoside and b) an agent that enhances penetration of said at least one deoxyribonucleoside into the skin.
- 110. A composition as in claim 109 wherein said skin is human skin.
- 111. A composition as in claim 109 wherein said at least one deoxyribonucleoside is deoxycytidine.
- 112. A composition as in claim 109 wherein said source of at least one deoxyribonucleoside is deoxyadenosine.
- 113. A composition as in claim 109 wherein said source of at least one deoxyribonucleoside is deoxyguanosine.
- 114. A composition as in claim 109 wherein said source of at least one deoxyribonucleoside is thymidine.
- 115. A composition as in claim 109 wherein said at least one deoxyribonucleoside is present in a concentration of from 0.1 to 10 milligrams per milliliter of each deoxyribonucleoside.
- 116. A composition as in claim 109 wherein said at least one deoxyribonucleoside is present in a concentration of from 1.0 to 5 milligrams per milliliter of each deoxyribonucleoside.
- 117. A composition as in claim 109 wherein said at least one deoxyribonucleoside is a mixture comprising free deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 118. A composition as in claim 117 wherein each deoxyribonucleoside is present in a concentration of 0.1 to 10 milligrams per milliliter.
- 119. A composition as in claim 117 wherein each deoxyribonucleoside is present in a concentration of 1 to 5 milligrams per milliliter.
- 120. A composition as in claim 109 wherein said agent that enhances penetration is selected from the group consisting of ethanol, isopropanol, azone (1-dodecylazacycloheptan-2-one), oleic acid, linoleic acid, propylene glycol, hypertonic glycerol, lactic acid, glycolic acid, citric acid, malic acid, and diethylene glycol monoethyl ether.
- 121. A composition as in claim 120 wherein said agent that enhances penetration is diethylene glycol monoethyl ether.
- 122. A composition as in claim 121 wherein said diethylene glycol monoethyl ether is present in a concentration of 2 to 20%.
- 123. A composition as in claim 121 wherein said diethylene glycol monoethyl ether is present in a concentration of 5 to 15%.
- 124. A composition as in claim 109 wherein said composition is a hydrogel.
- 125. A composition as in claim 124 wherein the gelling agent for said hydrogel is selected from the group consisting of methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, carbomer, Hypan, polyacrylate, and glycerine polyacrylate.
- 126. A composition as in claim 124 wherein the gelling agent for said hydrogel is carbomer.
- 127. A composition as in claim 126 wherein the concentration of said carbomer is 2 to 10%.
- 128. A composition comprising
a) deoxyguanosine and deoxyadenosine and b) benzyl alcohol.
- 129. A composition as in claim 128 wherein the concentration of said benzyl alcohol is between 0.1 and 5%.
- 130. A composition as in claim 128 wherein the concentrations of deoxyguanosine and deoxyadenosine are between 0.1 and 10 mg/ml.
- 131. A composition as in claim 128 further containing deoxycytidine and thymidine.
- 132. A composition as in claim 131 wherein the concentrations of deoxycytidine and thymidine are between 0.1 and 10 mg/ml.
- 133. A composition comprising a methylxanthine and source of at least one deoxyribonucleoside.
- 134. A composition as in claim 133 wherein said source of at least one deoxyribonucleoside is selected from the group consisting of at least one deoxyribonucleoside and at least one acyl derivative of a deoxyribonucleoside.
- 135. A composition comprising
a) a sunscreen agent b) an energy scavenging agent.
- 136. A composition as in claim 135 wherein said sunscreen agent is selected from the group consisting of avobenzone (t-butyl dimethoxydibenzoylmethane), oxybenzone (benzophenone-3), dioxybenzone (benzophenone-8), sulisobenzone (benzophenone-4; 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid), octocrylene (2-ethylhexyl-2-cyano-3,3-diphenylacrylate), octyl methoxycinnamate (2-ethylhexyl p-methoxycinnamate), octyl salicylate (2-ethylhexylsalicylate), homosalate (homomenthyl salicylate), trolamine salicylate (triethanolamine salicylate), phenylbenzimidazole sulfonic acid, PABA (para-aminobenzoic acid), roxadimate (ethyl 4-bis hydroxypropyl aminobenzoate), lisadimate (glyceryl PABA), Padimate O (octyldimethyl PABA), menthyl anthranilate, and Parsol 1789 (butyl methoxydibenzoylmethane).
- 137. A composition as in claim 135 wherein said energy scavenging agent is selected from the group consisting of a source of at least one deoxyribonucleoside.
- 138. A composition as in claim 137 wherein said source of at least one deoxyribonucleoside is selected from the group consisting of a deoxyribonucleoside, a deoxyribonucleotide, an oligodeoxyribonucleotide, or an acyl deoxyribonucleoside.
- 139. A composition as in claim 138 wherein said at least one deoxyribonucleoside is a mixture comprising free or acylated deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 140. A composition as in claim 138 wherein each deoxyribonucleoside is present in a concentration of from 0.1 to 10 milligrams per milliliter.
- 141. A composition as in claim 138 wherein said at least one deoxyribonucleoside is free or acyl deoxycytidine.
- 142. A composition as in claim 141 wherein said free or acyl deoxycytidine is present in a concentration of from 0.1 to 100 milligrams per milliliter.
- 143. A composition as in claim 135 wherein said energy scavenging agent is selected from the group consisting of a source of at least one ribonucleoside.
- 144. A composition as in claim 143 wherein said source of at least one deoxyribonucleoside is selected from the group consisting of a ribonucleoside, a ribonucleotide, an oligoribonucleotide, or an acyl ribonucleoside.
- 145. A method for reducing the rate of development of skin photodamage in a mammal exposed to solar or ultraviolet radiation comprising administering to the skin of said mammal a source of at least one deoxyribonucleoside wherein said source is administered such that said deoxyribonucleoside is present on skin of said mammal during or after exposure to said radiation in an amount sufficient to reduce the deleterious consequences of said exposure.
- 146. A method as in claim 145 wherein said source is selected from the group consisting of at least one free or acyl deoxyribonucleoside.
- 147. A method as in claim 145 wherein said source is selected from the group consisting of a deoxyribonucleotide, an oligodeoxyribonucleotide, and a polydeoxyribonucleotide.
- 148. A method of reducing the rate of development of skin photodamage in a mammal due to exposure to solar or ultraviolet radiation comprising topically administering a composition comprising a sunscreen agent and an energy scavenging agent.
- 149. A method as in claim 148 wherein said energy scavenging agent is selected from the group consisting of DNA, an oligodeoxyribonucleotide, a ribonucleoside, a deoxyribonucleoside, a ribonucleotide, a deoxyribonucleotide, an acyl deoxyribonucleoside, and an acyl ribonucleoside.
- 150. A method for inducing regression of inflammatory or hyperproliferative skin lesions due to exposure to solar or ultraviolet radiation comprising topically administering a composition comprising a source of at least one deoxyribonucleoside or deoxyribose.
- 151. A method as in claim 150 wherein said skin lesion is selected from the group comprising actinic keratosis, solar lentigines, psoriasis, dermatitis, eczemea, melanoma, basal cell carcinoma, and squamous cell carcinoma.
- 152. A method as in claim 150 wherein said source of at least one deoxyribonucleoside is selected from the group consisting of a deoxyribonucleoside, a deoxyribonucleotide, an oligodeoxyribonucleotide, or an acyl deoxyribonucleoside.
- 153. A method as in claim 152 wherein said at least one deoxyribonucleoside is a mixture comprising free or acylated deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine.
- 154. A method as in claim 152 wherein each deoxyribonucleoside is present in a concentration of from 0.1 to 10 milligrams per milliliter.
- 155. A method as in claim 152 wherein said at least one deoxyribonucleoside is free or acyl deoxycytidine.
- 156. A method as in claim 155 wherein said free or acyl deoxycytidine is present in a concentration of from 0.1 to 100 milligrams per milliliter.
- 157. A method as in claim 150 wherein said deoxyribose is present in a topical formulation in a concentration of 0.1 to 100 millimolar.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. application Ser. No. 08/963831 filed Nov. 4, 1997, herein incorporated by reference.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09185084 |
Nov 1998 |
US |
Child |
09871973 |
Jun 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08963831 |
Nov 1997 |
US |
Child |
09185084 |
Nov 1998 |
US |